HonCode

Go Back   HER2 Support Group Forums > Articles of Interest
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Reply
 
Thread Tools Display Modes
Old 11-17-2006, 03:49 AM   #1
Lani
Senior Member
 
Join Date: Mar 2006
Posts: 4,778
new method for early detection of breast cancer

Ann N Y Acad Sci. 2006 Sep;1075:235-243. Links
Cell-free DNA and RNA in Plasma as a New Molecular Marker for Prostate and Breast Cancer.

Papadopoulou E,
Davilas E,
Sotiriou V,
Georgakopoulos E,
Georgakopoulou S,
Koliopanos A,
Aggelakis F,
Dardoufas K,
Agnanti NJ,
Karydas I,
Nasioulas G.
Molecular Biology Research Center HYGEIA Antonis Papayiannis, Kifissias Ave. and Erythrou Stavrou 4 Str., 15123 Maroussi, Athens, Greece. g.nasioul@hygeia.gr.
In this study, we examined several molecular markers in prostate and breast cancer patients and in normal individuals. The markers tested were: variations in the quantity of plasma DNA, glutathione-S-transferase P1 gene (GSTP1), Ras association domain family 1A (RASSF1A), and ataxia telangiectasia mutated (ATM) methylation status in plasma, carcinoembryonic antigen (CEA) and prostate-specific membrane antigen (PSMA) mRNA in peripheral blood mononuclear cells (PBMC) and plasma samples from prostate cancer patients. DNA quantification in plasma was performed using real-time PCR (RT-PCR). We assessed the methylation status of GSTP1 in plasma DNA using methylation-specific PCR (MSP) assay, while the methylation status of RASSF1A and ATM genes was examined by the MethyLight technology. RT-PCR analysis was used for the detection of mRNA, PSMA, and CEA. In 58.3% of newly diagnosed prostate cancer patients and 26.7% of prostate cancer patients under therapy, plasma DNA levels were increased. Additionally, 48.5% of breast cancer patients showed plasma DNA levels above the cutoff limit. GSTP1 Promotor hypermethylation was detectable in 75% of plasma samples obtained from patients with newly diagnosed prostate cancer and in 36.8% of patients under therapy, whereas 26% and 14% of the breast cancer patients tested were positive for RASSF1A and ATM methylation, respectively. The combination of DNA load and promotor methylation status identified 88% of prostate cancer patients and 54% of breast cancer patients. This study shows that free-circulating DNA can be detected in cancer patients compared with disease-free individuals, and suggests a new, noninvasive approach for early detection of cancer.
PMID: 17108217 [PubMed -
Lani is offline   Reply With Quote
Old 11-18-2006, 02:50 PM   #2
RobinP
Senior Member
 
RobinP's Avatar
 
Join Date: Nov 2005
Posts: 943
I've heard that Dr. Coignet who invented the PSA is onto a breast cancer blood screening test called the coignet test. Great things on the horizon, huh?
__________________
Robin
2002- dx her2 positive DCIS/bc TX Mast, herceptin chemo
RobinP is offline   Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On

Forum Jump


All times are GMT -7. The time now is 02:04 AM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter